We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HER2

News List

IGEM gets further funding for cancer drugs pharmatimes
April 04, 2019
IGEM Therapeutics has received a £750,000 grant from Innovate UK Biomedical Catalyst Primer Award.
Trastuzumab Tied to Higher Long-Term Risk for Heart Failure drugs
March 21, 2019
Compared with chemotherapy alone, trastuzumab is associated with a twofold increased long-term risk for heart failure in breast cancer survivors, according to a study published in the March 1 issue of JACC: Heart Failure.
Prestige, Cipla unite to sell cancer biosimilar HD201 biospectrumasia
December 17, 2018
HD201 is a mAb biosimilar to Roche’s Herceptin® which is used to treat patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Previous page 1 2 Next page